Related Experiment Video
Updated: Jul 16, 2026
23:33
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
One-year follow-up of the amplatzer device to close atrial septal defects
1Heart Center, Children's Hospital Medical Center, Cincinnati, Ohio 45229-3039, USA. taeer0@chmcc.org
The American Journal of Cardiology
|January 4, 2001
Insights
This study followed patients who received the Amplatzer atrial septal defect closure device. All patients achieved complete closure of their atrial septal defect within one year.
Area of Science:
- Cardiovascular Medicine
- Interventional Cardiology
- Medical Device Technology
Background:
- Atrial septal defects (ASDs) are congenital heart conditions requiring intervention.
- Percutaneous closure devices offer a minimally invasive treatment option for ASDs.
Purpose of the Study:
- To report the early and 1-year outcomes of the Amplatzer atrial septal defect closure device.
- To evaluate the efficacy of the Amplatzer device in achieving complete closure of ASDs.
Main Methods:
- A single-center study was conducted in the United States.
- Patients underwent implantation of the Amplatzer atrial septal defect closure device.
- Follow-up included early assessment and 1-year evaluation of device performance.
Main Results:
- Complete closure of the atrial septal defect was documented in all patients.
- The efficacy of the Amplatzer device was confirmed at the 1-year follow-up point.
Conclusions:
- The Amplatzer atrial septal defect closure device demonstrates high efficacy in achieving complete closure.
- Percutaneous closure with the Amplatzer device is a successful treatment option for atrial septal defects.
Abstract:
The early and 1-year follow-up of a single United States center using the Amplatzer atrial septal defect closure device is reported. Complete closure was documented in all patients by 1 year after device implantation.
